<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624128</url>
  </required_header>
  <id_info>
    <org_study_id>V-CHANCE</org_study_id>
    <secondary_id>2014-001523-69</secondary_id>
    <nct_id>NCT02624128</nct_id>
  </id_info>
  <brief_title>Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck</brief_title>
  <acronym>V-CHANCE</acronym>
  <official_title>Preclinical and Clinical Study of Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      V-CHANCE is a phase 2, trial exploring the feasibility and the activity of valproic acid&#xD;
      (VPA) in combination with the standard cisplatin-cetuximab combination in patients with&#xD;
      recurrent/metastatic squamous cell carcinoma of the head and neck, never treated with&#xD;
      first-line chemotherapy. The study includes an explorative analysis of the potential&#xD;
      prognostic or predictive role of several biomarkers with the aim of improving the knowledge&#xD;
      of the mechanisms by which VPA enhances chemotherapy effect and of identifying early&#xD;
      predictors of treatment response/resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 23, 2015</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Actual">April 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with an objective response</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Response will be assessed according to RECIST v1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to tumor progression</measure>
    <time_frame>up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to 18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>valproic acid plus cisplatin and cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.</description>
    <arm_group_label>valproic acid plus cisplatin and cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles</description>
    <arm_group_label>valproic acid plus cisplatin and cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly</description>
    <arm_group_label>valproic acid plus cisplatin and cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically proven squamous cell carcinoma of head and neck with&#xD;
             exclusion of the nasopharynx&#xD;
&#xD;
          2. First-line recurrent and/or metastatic disease&#xD;
&#xD;
          3. No prior chemotherapy except for chemoradiation or induction chemotherapy followed by&#xD;
             local treatment given in the context of a curative strategy.&#xD;
&#xD;
          4. age&gt; 18 years&#xD;
&#xD;
          5. ECOG Performance Status ≤1&#xD;
&#xD;
          6. Life expectancy at least 3 months at study entrance&#xD;
&#xD;
          7. Normal bone marrow reserve (absolute neutrophil count &gt; 1500/mm3; platelets &gt;&#xD;
             100000/mm3; haemoglobin&gt; 9 g/dl)&#xD;
&#xD;
          8. Normal hepatic function (total serum bilirubin &lt; 1.5 x upper limit of normal; liver&#xD;
             transaminases &lt; 3 x upper limit of normal)&#xD;
&#xD;
          9. Normal renal function (serum creatinine &lt; 1,25 x upper limit of normal and creatinine&#xD;
             clearance &gt; 60 ml/min).&#xD;
&#xD;
         10. Normal cardiac function (assessed by ECG and echocardiography with ejection fraction &gt;&#xD;
             50%)&#xD;
&#xD;
         11. Effective contraception for both male and female patients if the risk of conception&#xD;
             exist&#xD;
&#xD;
         12. Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concomitant treatment with other experimental drugs.&#xD;
&#xD;
          2. Brain metastases (CT scan or MRI required only in case of clinical suspicion of CNS&#xD;
             metastases)&#xD;
&#xD;
          3. Non squamous cell histology&#xD;
&#xD;
          4. Any concurrent malignancy. Patient with a previous malignancy but without evidence of&#xD;
             disease for 5 years will be allowed to enter the trial.&#xD;
&#xD;
          5. History of myocardial infarction within the last 12 months&#xD;
&#xD;
          6. ECOG PS ≥ 2&#xD;
&#xD;
          7. Significant cardiovascular comorbidity (e.g. myocardial infarction, superior vena cava&#xD;
             [SVC] syndrome, patients with an ejection fraction of &lt;50%) or presence of cardiac&#xD;
             disease that in the opinion of the Investigator increases the risk of ventricular&#xD;
             arrhythmia.&#xD;
&#xD;
          8. History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy,&#xD;
             trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is&#xD;
             symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained&#xD;
             ventricular tachycardia. Patients with long QT-syndrome or QTc interval duration &gt; 480&#xD;
             msec or concomitant medication with drugs prolonging QTc.&#xD;
&#xD;
          9. HIV positive patients&#xD;
&#xD;
         10. Patients who cannot take oral medication, who require intravenous feeding, have had&#xD;
             prior surgical procedures affecting absorption, or have active peptic ulcer disease.&#xD;
&#xD;
         11. Known or suspected hypersensitivity to any of the study drugs.&#xD;
&#xD;
         12. Patients who have had prior treatment with an HDAC inhibitor and patients who have&#xD;
             received compounds with HDAC inhibitor-like activity, such as valproic acid.&#xD;
&#xD;
         13. Major surgical procedure within 28 days prior to study treatment start.&#xD;
&#xD;
         14. Pregnant or lactating women.&#xD;
&#xD;
         15. Women of childbearing potential with either a positive or no pregnancy test at&#xD;
             baseline (postmenopausal women must have been amenorrheic for at least 12 months to be&#xD;
             considered of non-childbearing potential)l.&#xD;
&#xD;
         16. Sexually active males and females (of childbearing potential) unwilling to practice&#xD;
             contraception during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Caponigro, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Budillon, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 26, 2015</study_first_submitted>
  <study_first_submitted_qc>December 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2015</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck cancer</keyword>
  <keyword>valproic acid</keyword>
  <keyword>recurrent</keyword>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

